ANTI-CD33 AND NKG2D LIGAND CHIMERAS FOR TREATMENT OF MYELOID MALIGNANCIESDisclosed herein are compositions and methods relating to fusion proteins that target a lineage-specific cell-surface antigen for treating hematological malignancies.MUKHERJEE, SIDDHARTHA...
NKT-cell-ligand-loaded antigen-presenting cell (APC)-based tumour Ag-expressing vaccination efficiently induced the eradication of tumours containing MHC class I-deficient cells. From this perspective, we hypothesized that NK anergy in mice bearing MHC class I-...
, CLN-619, a Clinical-Stage MICA/MICB-specific IgG1 Antibody, Restores the MICA/MICB-NKG2D axis to Promote NK-Mediated Tumor Cell Lysis, AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, Cancer Research, PHILADELPHIA, PA (2022) Google Scholar [24] G. Chitadze, M. Lettau, C. ...
While the effector cells that mediate anti-tumor immunity have historically been attributed to αβ T cells and natural killer cells, γδ T cells are now being recognized as a complementary mechanism mediating tumor rejection. γδ T cells possess a hos
24,25 However, whether NKG2D CAR-NK cells can be used to treat AML, either in preclinical or clinical studies, remains to be an open question. A key obstacle to CAR-NK cell therapy is genetic modification of primary NK cells to achieve stable CAR expression. For CAR-T cell manufacturing,...
(klebsiella), stimulates a lung-specific anti-cancer immune response, including macrophage recruitment and m1 polarization, nk cell recruitment and activation, and upregulation of the nkg2d pathway [140]. qbkpn reduces lung-cancer burden in mouse models and downregulates pd-1 and pd-l1 systemically...
NK cell immuno therapy, and provide an overview of the evolving engi- neering strategies to augment NK cell potency and persistence, as well as the efforts to redirect NK cell specificity to tumours through next-generation CAR molecules, engineered TCR and pre-complexing with cell engagers. ...
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734 (2002). CAS PubMed Google Scholar Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D. & Freedman, R. S. Identification of an IL-10-producing HLA-DR-negative ...
NK cells bind to target cells through multiple receptors, including natural cytotoxicity receptors (NCR), the Fc receptor CD 16, NKG2D, and others. Binding of ligand to receptor initiates tyrosine phosphorylation and recruitment of accessory signaling molecules. This cascade results in activation of ...
NK cells bind to target cells through multiple receptors, including natural cytotoxicity receptors (NCR), the Fc receptor CD16, NKG2D, and others. Binding of ligand to receptor initiates tyrosine phosphorylation and recruitment of accessory signaling molecules. This cascade results in activation of the...